Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Immaculada Raurell Saborit

Immaculada Raurell Saborit

Institutions of which they are part

Postdoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca
Immaculada Raurell Saborit

Immaculada Raurell Saborit

Immaculada Raurell Saborit

Institutions of which they are part

Postdoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

NANOPARTICULAS BIODEGRADABLES DE SIMVASTATINA COMO NUEVA HERRAMIENTA TERAPÉUTICA PARA LA ENFERMEDAD HEPÁTICA CRÓNICA

IP: Maria Nieves Martell Pérez-Alcalde
Collaborators: Immaculada Raurell Saborit, Victor Manuel Vargas Blasco, Ester Palacio Gutierrez
Funding agency: Instituto de Salud Carlos III
Funding: 75020
Reference: PI17/00754
Duration: 01/01/2018 - 31/12/2020

Investigación traslacional en complicaciones de la cirrosis: del modelo experimental a la clínica y viceversa

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Macarena Simon-Talero Horga, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 130075
Reference: PI15/00066
Duration: 01/01/2016 - 31/10/2019

Malalties Hepatobiliars (GRC)

IP: Rafael Esteban Mur
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Francisco Rodríguez Frias, Silvia Sauleda Oliveras, Victor Manuel Vargas Blasco, Maria Buti Ferret, Torrens Buscató, Maria Margarita, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Mecanismos de neuromodulación en la hipertensión portal: nuevas posibilidades terapéuticas en la cirrosis hepática

IP: Maria Nieves Martell Pérez-Alcalde
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 69575
Reference: PI13/01289
Duration: 01/01/2014 - 30/06/2017

Related news

Grup de Malalties Hepàtiques del VHIR

A clinical trial has led to approval of the first drug for advanced fatty liver disease

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Equip projecte ARTEMIs

We study fatty liver and cardiovascular complications with digital twins

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Les Drs. María Martell i Ibane Abasolo

New treatment based on nanoparticles for chronic liver disease

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

See more

Related professionals

Cristina Vetoret Vázquez

Cristina Vetoret Vázquez

Research assistant
Clinical Neuroimmunology
Read more
Melissa Bradbury Lobato

Melissa Bradbury Lobato

Biomedical Research in Gynaecology
Read more
Norberto Núñez Seral

Norberto Núñez Seral

Tècnic/a Superior Recerca
High Technology Unit (UAT)
Preclinical Core Facilities
Core Facilities Area
Read more
María Puigcerver Mas

María Puigcerver Mas

Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.